Orthotopic Heart Transplantations in a Newly Opened Transplantation Center in Poland: Population Description and Prognosis
- 1Institute of Heart Diseases, University Hospital in Wrocław, 50-556 Wroclaw, Poland
- 2Clinic of Cardiac Transplantation and Mechanical Circulatory Support, Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland
- 3Institute of Heart Diseases, Student Scientific Club of Transplantology and Advanced Therapies of Heart Failure, Wroclaw Medical University, 50-556 Wrocław, Poland
Abstract
Introduction: Heart transplantation (HTx) remains the definitive treatment for selected patients with advanced heart failure. The early post-transplant period is characterized by substantial morbidity and requires intensive surveillance. The aim of this study was to describe the clinical course of the first 100 heart transplant recipients treated at our newly established center, with particular emphasis on in-hospital outcomes and the 12-month follow-up. Methods: We retrospectively analyzed 100 consecutive patients who underwent orthotopic HTx between February 2021 and May 2023 at our center. Demographic, clinical, hemodynamic, laboratory, treatment, and post-transplant follow-up data were collected. The follow-up assessment included survival, rejection, infectious complications, renal replacement therapy (RRT), heart failure decompensation, hospitalizations, outpatient visits, and changes in pharmacotherapy. Cox proportional hazards regression and Receiver Operating Characteristic (ROC) analyses were also performed to assess factors associated with 12-month mortality. Results: The study population comprised 82 (82%) men and 18 (18%) women with a median age of 54 years (IQR, 45–64). The in-hospital course was characterized by substantial early morbidity: 17 patients (17%) died during the index hospitalization, with a median time to death of 17 days (IQR, 3–78). RRT was required in 44% of patients. Among hospital survivors, the median length of hospital stay was 43 days and the median ICU stay was 7 days. During the 12-month follow-up, clinically significant cellular graft rejection (grade ≥ 3) occurred at least once in 51% of patients, infectious complications in 45%, and one patient underwent retransplantation. The twelve-month all-cause mortality was 23%. Patients had a mean of 8 planned hospitalizations, 0.4 unplanned admissions, and 1.3 outpatient visits per patient. Exploratory analyses identified possible associations between selected pre-transplant variables and 12-month mortality. Conclusions: The first 100 HTx recipients treated at the newly established center experienced a clinically demanding in-hospital course, with a 17% in-hospital mortality. After discharge, the first year remained characterized by frequent cellular rejection incidence, and infectious complications. The twelve-month survival was 77%. These findings provide a comprehensive description of the early in-hospital and 12-month clinical course of a newly established Htx program.
Related
- Expanding the Donor Pool in Pediatric Transplantations: Successful Domino Liver Transplantation From the Youngest Reported Pediatric DCD Donor Using Normothermic Regional Perfusion in the United States
- Orthotopic heart transplantation associated with hemiarch reconstruction for advanced heart failure and chronic aortic dissection: a case report.
- Improvement in pulmonary vascular resistance with IMPELLA 5.5 as a bridge to orthotopic heart transplantation
- PO128 | FROM SEVERE THROMBOSIS TO SUCCESSFUL PREGNANCIES: ORTHOTOPIC LIVER TRANSPLANTATION IN INHERITED AFIBRINOGENEMIA WITH BUDD–CHIARI SYNDROME
- Clinical characteristics and prognosis of T1N0M1 lung cancer: a population-based retrospective study
BibTeX
@article{sokolski2026orthotopic,
title = {{Orthotopic Heart Transplantations in a Newly Opened Transplantation Center in Poland: Population Description and Prognosis}},
author = {Mateusz Sokolski and Jakub Ptak and Michał Wilk and Wiktoria Zychla and Paulina Tomecka and Maciej Szwajkowski and Małgorzata Makieła and Magdalena Cielecka and Mateusz Rakowski and Maciej Bochenek and Roman Przybylski and Michał Zakliczyński},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15218229},
url = {https://www.mdpi.com/2077-0383/15/21/8229},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Orthotopic Heart Transplantations in a Newly Opened Transplantation Center in Poland: Population Description and Prognosis
AU - Mateusz Sokolski
AU - Jakub Ptak
AU - Michał Wilk
AU - Wiktoria Zychla
AU - Paulina Tomecka
AU - Maciej Szwajkowski
AU - Małgorzata Makieła
AU - Magdalena Cielecka
AU - Mateusz Rakowski
AU - Maciej Bochenek
AU - Roman Przybylski
AU - Michał Zakliczyński
PY - 2026
DA - 2026/10/22
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218229
UR - https://www.mdpi.com/2077-0383/15/21/8229
AB - Introduction: Heart transplantation (HTx) remains the definitive treatment for selected patients with advanced heart failure. The early post-transplant period is characterized by substantial morbidity and requires intensive surveillance. The aim of this study was to describe the clinical course of the first 100 heart transplant recipients treated at our newly established center, with particular emphasis on in-hospital outcomes and the 12-month follow-up. Methods: We retrospectively analyzed 100 consecutive patients who underwent orthotopic HTx between February 2021 and May 2023 at our center. Demographic, clinical, hemodynamic, laboratory, treatment, and post-transplant follow-up data were collected. The follow-up assessment included survival, rejection, infectious complications, renal replacement therapy (RRT), heart failure decompensation, hospitalizations, outpatient visits, and changes in pharmacotherapy. Cox proportional hazards regression and Receiver Operating Characteristic (ROC) analyses were also performed to assess factors associated with 12-month mortality. Results: The study population comprised 82 (82%) men and 18 (18%) women with a median age of 54 years (IQR, 45–64). The in-hospital course was characterized by substantial early morbidity: 17 patients (17%) died during the index hospitalization, with a median time to death of 17 days (IQR, 3–78). RRT was required in 44% of patients. Among hospital survivors, the median length of hospital stay was 43 days and the median ICU stay was 7 days. During the 12-month follow-up, clinically significant cellular graft rejection (grade ≥ 3) occurred at least once in 51% of patients, infectious complications in 45%, and one patient underwent retransplantation. The twelve-month all-cause mortality was 23%. Patients had a mean of 8 planned hospitalizations, 0.4 unplanned admissions, and 1.3 outpatient visits per patient. Exploratory analyses identified possible associations between selected pre-transplant variables and 12-month mortality. Conclusions: The first 100 HTx recipients treated at the newly established center experienced a clinically demanding in-hospital course, with a 17% in-hospital mortality. After discharge, the first year remained characterized by frequent cellular rejection incidence, and infectious complications. The twelve-month survival was 77%. These findings provide a comprehensive description of the early in-hospital and 12-month clinical course of a newly established Htx program.
SN - 2077-0383
ER -